THE JOURNAL · RESEARCH TRACKER

Psilocybin clinical trials in Canada.

Name: Psilocybin clinical trials with a Canadian site
Creator: Shroomverse

Yes, there are psilocybin trials in Canada: on 2 November 2026, ClinicalTrials.gov listed 41 studies testing psilocybin with a Canadian site, 16 of them recruiting. This page lists every one from that registry, which is run by the US National Library of Medicine, and refreshes every day.

This is a list of research studies, not treatment or medical advice. Each study’s team decides who can take part, and Shroomverse has no connection to any study listed. If a study interests you, its registry record lists eligibility and contacts; talk it over with your doctor. For how legal access to psilocybin works in Canada, see psilocybin-assisted therapy in Canada.

41 studies with a Canadian site

16 recruiting now

4 not yet recruiting

21 Canadian cities

Registry data checked 2 November 2026. Source: ClinicalTrials.gov.

By status

Recruiting16 of 41 trials
Not yet recruiting4 of 41 trials
Under way9 of 41 trials
Completed7 of 41 trials
Stopped2 of 41 trials
Status unknown3 of 41 trials

By province (a study can have sites in several)

Ontario31 of 41 trials
British Columbia8 of 41 trials
Alberta6 of 41 trials
Quebec2 of 41 trials
Nova Scotia2 of 41 trials

By condition studied (a study can count in several)

Depression18 of 41 trials
Distress in serious illness7 of 41 trials
Alcohol and drug use5 of 41 trials
PTSD and trauma4 of 41 trials
Anxiety2 of 41 trials
Pain3 of 41 trials
Other7 of 41 trials

All trials

Province

Showing 41 of 41 trials

RecruitingPhase 2 / Phase 3300 participants planned
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Conditions
PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms; PTSD, Post Traumatic Stress Disorder
Canadian sites
North Vancouver, British Columbia
Lead sponsor
COMPASS Pathways
Dates
Start Sep 2026 · main results expected Nov 2028
NCT07570654 on ClinicalTrials.gov · record updated Oct 2026
RecruitingPhase 240 participants planned
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Conditions
Treatment-Resistant Depression
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Jul 2026 · main results expected Jul 2028
NCT07211438 on ClinicalTrials.gov · record updated Aug 2026
RecruitingPhase 290 participants planned
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
Conditions
Bipolar II Depression
Canadian sites
Vancouver, British Columbia; Ottawa, Ontario; Toronto, Ontario
Lead sponsor
Lakshmi N Yatham
Dates
Start Jun 2026 · main results expected Dec 2028
NCT06943573 on ClinicalTrials.gov · record updated Sep 2026
RecruitingPhase 2128 participants planned
Subjective Experience Following Psilocybin
Conditions
Investigating the Importance of the Subjective Psychedelic Experience
Canadian sites
Calgary, Alberta
Lead sponsor
University of Calgary
Dates
Start May 2026 · main results expected Dec 2027
NCT06768944 on ClinicalTrials.gov · record updated Sep 2026
RecruitingPhase 115 participants planned
Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer
Conditions
Demoralization; Safety
Canadian sites
Kingston, Ontario
Lead sponsor
Gustavo Vazquez
Dates
Start Apr 2026 · main results expected Jun 2027
NCT06818994 on ClinicalTrials.gov · record updated Mar 2026
RecruitingPhase 230 participants planned
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
Conditions
Major Depressive Disorder (MDD); Alcohol Use Disorder (AUD)
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Mar 2026 · main results expected Mar 2028
NCT07405606 on ClinicalTrials.gov · record updated Oct 2026
RecruitingPhase 3120 participants planned
Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)
Conditions
Psychological Distress
Canadian sites
Brampton, Ontario; Kingston, Ontario; London, Ontario; Newmarket, Ontario; Ottawa, Ontario; Montreal, Quebec
Lead sponsor
Bruyère Health Research Institute.
Dates
Start Jan 2026 · main results expected Aug 2027
NCT07063862 on ClinicalTrials.gov · record updated Jul 2026
RecruitingPhase 210 participants planned
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication
Conditions
Opioid Dependence; Chronic Pain
Canadian sites
Kelowna, British Columbia
Lead sponsor
University of British Columbia
Dates
Start Oct 2025 · main results expected Aug 2026
NCT05585229 on ClinicalTrials.gov · record updated Dec 2025
RecruitingPhase 215 participants planned
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer
Conditions
Caregiver Distress
Canadian sites
Toronto, Ontario
Lead sponsor
University Health Network, Toronto
Dates
Start Jul 2025 · main results expected Dec 2027
NCT07048743 on ClinicalTrials.gov · record updated Jun 2026
RecruitingPhase 250 participants planned
A Randomized Neuroimaging Trial of Psilocybin in Depression
Conditions
Depressive Disorder; Major Depressive Disorder
Canadian sites
Toronto, Ontario
Lead sponsor
Sunnybrook Health Sciences Centre
Dates
Start May 2025 · main results expected May 2028
NCT06072898 on ClinicalTrials.gov · record updated Mar 2026
RecruitingPhase 140 participants planned
Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy
Conditions
Persisting Symptoms After Concussion
Canadian sites
Calgary, Alberta
Lead sponsor
University of Calgary
Dates
Start May 2025 · main results expected Jun 2027
NCT06615908 on ClinicalTrials.gov · record updated Sep 2026
RecruitingPhase 250 participants planned
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Conditions
Generalized Anxiety Disorder (GAD)
Canadian sites
Kingston, Ontario
Lead sponsor
Claudio N Soares
Dates
Start May 2025 · main results expected Dec 2027
NCT06969170 on ClinicalTrials.gov · record updated Aug 2026
RecruitingPhase 212 participants planned
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Conditions
Treatment Resistant Depression
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Apr 2025 · main results expected Apr 2027
NCT06512220 on ClinicalTrials.gov · record updated Oct 2026
RecruitingPhase 216 participants planned
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
Conditions
Treatment Resistant Depression; Chronic Pain
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Apr 2025 · main results expected Mar 2027
NCT06518720 on ClinicalTrials.gov · record updated Oct 2026
RecruitingPhase 230 participants planned
Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN
Conditions
Chronic Neuropathic Pain; Pain Management
Canadian sites
Toronto, Ontario
Lead sponsor
Unity Health Toronto
Dates
Start Mar 2025 · main results expected Aug 2026
NCT06731335 on ClinicalTrials.gov · record updated Mar 2025
RecruitingPhase 2128 participants planned
Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Conditions
Alcohol Use Disorder; Alcoholism
Canadian sites
Calgary, Alberta
Lead sponsor
University of Calgary
Dates
Start Mar 2024 · main results expected Oct 2027
NCT05995769 on ClinicalTrials.gov · record updated May 2024
Not yet recruitingPhase 260 participants planned
MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial
Conditions
Advanced Cancer; Demoralization; Existential Distress; Psychological Distress
Canadian sites
Calgary, Alberta; Kingston, Ontario
Lead sponsor
University of Calgary
Dates
Start Oct 2026 · main results expected Dec 2027
NCT07791901 on ClinicalTrials.gov · record updated Sep 2026
Not yet recruitingPhase 276 participants planned
Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence
Conditions
Post Traumatic Stress Disorder PTSD; Intimate Partner Violence (IPV)
Canadian sites
Calgary, Alberta; Kelowna, British Columbia
Lead sponsor
University of Calgary
Dates
Start Oct 2026 · main results expected Aug 2028
NCT06885996 on ClinicalTrials.gov · record updated Sep 2026
Not yet recruitingPhase 246 participants planned
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial
Conditions
Advanced Cancer; Stage IV Solid Tumor Cancer; Stage IV Sarcoma of Bone; Stage IV Lymphoma; Stage IV Melanoma; Endocrine Cancer
Canadian sites
Toronto, Ontario
Lead sponsor
University Health Network, Toronto
Dates
Start Sep 2026 · main results expected Dec 2028
NCT07820033 on ClinicalTrials.gov · record updated Oct 2026
Not yet recruitingPhase 216 participants planned
Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy
Conditions
Treatment-Resistant Major Depressive Disorder
Canadian sites
Montreal, Quebec
Lead sponsor
Kyle Greenway
Dates
Start May 2026 · main results expected Jul 2028
NCT07373535 on ClinicalTrials.gov · record updated Apr 2026
Enrolling by invitationNot applicable65 participants planned
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Conditions
Treatment-resistant Depression (TRD)
Canadian sites
Toronto, Ontario
Lead sponsor
Joshua Rosenblat
Dates
Start Jul 2026 · main results expected Dec 2029
NCT07737990 on ClinicalTrials.gov · record updated Jul 2026
Active, not recruitingPhase 215 participants planned
Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD
Conditions
Post Traumatic Stress Disorder; PTSD; Chronic PTSD
Canadian sites
Toronto, Ontario
Lead sponsor
Unity Health Toronto
Dates
Start Jun 2026 · main results expected Jan 2028
NCT06386003 on ClinicalTrials.gov · record updated Oct 2026
Active, not recruitingPhase 216 participants planned
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
Conditions
Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe
Canadian sites
Hamilton, Ontario
Lead sponsor
McMaster University
Dates
Start Mar 2025 · main results expected Dec 2026
NCT06225232 on ClinicalTrials.gov · record updated Aug 2026
Active, not recruitingPhase 118 participants planned
Psilocybin for Treatment-Resistant Depression in Autism
Conditions
Treatment Resistant Depression; Autism Spectrum Disorder
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Nov 2024 · main results expected Jan 2027
NCT06731621 on ClinicalTrials.gov · record updated Oct 2026
Active, not recruitingPhase 130 participants planned
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
Conditions
Bipolar Depression
Canadian sites
Toronto, Ontario
Lead sponsor
University Health Network, Toronto
Dates
Start Oct 2024 · main results expected Sep 2026
NCT06506019 on ClinicalTrials.gov · record updated Aug 2026
Active, not recruitingPhase 215 participants planned
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
Conditions
Advanced Cancer; Stage IV Solid Tumor Cancer; Stage IV Sarcoma of Bone; Stage IV Lymphoma; Stage IV Melanoma; Endocrine Cancer
Canadian sites
Toronto, Ontario
Lead sponsor
University Health Network, Toronto
Dates
Start Jun 2024 · main results expected Dec 2026
NCT06416085 on ClinicalTrials.gov · record updated Jun 2026
Active, not recruitingPhase 292 participants planned
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
Conditions
Major Depressive Disorder; Depression; Treatment-Resistant Depression; Mood Disorders
Canadian sites
Toronto, Ontario
Lead sponsor
University Health Network, Toronto
Dates
Start Feb 2024 · main results expected Jul 2026
NCT06341426 on ClinicalTrials.gov · record updated Jul 2026
Active, not recruitingPhase 1 / Phase 220 participants planned
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)
Conditions
Depression, Anxiety; Distress, Emotional
Canadian sites
Ottawa, Ontario
Lead sponsor
Ottawa Hospital Research Institute
Dates
Start Jan 2024 · main results expected Oct 2026
NCT04754061 on ClinicalTrials.gov · record updated Jul 2026
Active, not recruitingPhase 3572 participants planned
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Conditions
Treatment Resistant Depression
Canadian sites
Québec, British Columbia; Kamloops, British Columbia; Kelowna, British Columbia; Penticton, British Columbia; Chatham, Ontario; Toronto, Ontario; Vancouver, British Columbia
Lead sponsor
COMPASS Pathways
Dates
Start Feb 2023 · main results expected Nov 2025
NCT05711940 on ClinicalTrials.gov · record updated Aug 2026
CompletedPhase 110 participants planned
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
Conditions
Obsessive-Compulsive Disorder
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Sep 2024 · main results expected Sep 2026
NCT06299319 on ClinicalTrials.gov · record updated Sep 2026
CompletedPhase 210 participants planned
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
Conditions
Amnestic Mild Cognitive Impairment
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Nov 2023 · main results expected Feb 2026
NCT06041152 on ClinicalTrials.gov · record updated Oct 2026
CompletedPhase 239 participants planned
Microdosing Psychedelics to Improve Mood
Conditions
Major Depressive Disorder
Canadian sites
Toronto, Ontario
Lead sponsor
Rotem Petranker
Dates
Start Jul 2023 · main results expected Dec 2024
NCT05259943 on ClinicalTrials.gov · record updated Oct 2026
CompletedPhase 241 participants planned
Does Psilocybin Require Psychedelic Effects to Treat Depression?
Conditions
Treatment-resistant Depression
Canadian sites
Toronto, Ontario
Lead sponsor
Centre for Addiction and Mental Health
Dates
Start Jul 2023 · main results expected Apr 2026
NCT05710237 on ClinicalTrials.gov · record updated May 2026
CompletedPhase 230 participants planned
Psilocybin for Treatment-Resistant Depression
Conditions
Treatment Resistant Depression
Canadian sites
Mississauga, Ontario
Lead sponsor
Brain and Cognition Discovery Foundation
Dates
Start Nov 2021 · main results expected Jul 2023
NCT05029466 on ClinicalTrials.gov · record updated Jul 2023
CompletedPhase 156 participants planned
Identification of a Safe and Non-Psychedelic Dose of Psilocybin
Conditions
Healthy Controls
Canadian sites
Toronto, Ontario
Lead sponsor
Diamond Therapeutics Inc.
Dates
Start Oct 2021 · main results expected Mar 2022
NCT07710027 on ClinicalTrials.gov · record updated Jul 2026
CompletedPhase 2233 participants planned
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Conditions
Treatment Resistant Depression
Canadian sites
Mississauga, Ontario; Toronto, Ontario
Lead sponsor
COMPASS Pathways
Dates
Start Mar 2019 · main results expected Jul 2021
NCT03775200 on ClinicalTrials.gov · record updated Apr 2023
SuspendedPhase 210 participants planned
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Conditions
Fragile X Syndrome; Behavior; Cognitive Dysfunction
Canadian sites
London, Ontario
Lead sponsor
Nova Mentis Life Science Corp
Dates
Start Mar 2023 · main results expected May 2024
NCT05832255 on ClinicalTrials.gov · record updated May 2024
WithdrawnPhase 20 participants planned
Effect of SSRIs on Response to Psilocybin Therapy
Conditions
Depression; Major Depressive Disorder; Mild Depression; Moderate Depression; Depressive Disorder
Canadian sites
Abbotsford British Columbia, British Columbia
Lead sponsor
Cybin Therapeutics Inc.
Dates
Start Jan 2023 · main results expected Mar 2023
NCT05594667 on ClinicalTrials.gov · record updated Jul 2023
Status unknownPhase 1 / Phase 232 participants planned
Psychedelic-assisted Group Program for First Responders
Conditions
Psilocybin; Psychotherapy, Group
Canadian sites
Surrey, British Columbia
Lead sponsor
Empower Research Inc
Dates
Start Jan 2025 · main results expected Jul 2025
NCT06471959 on ClinicalTrials.gov · record updated Jun 2024
Status unknownPhase 220 participants planned
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Conditions
Treatment Resistant Disorders; Post Traumatic Stress Disorder
Canadian sites
Windsor, Nova Scotia
Lead sponsor
Halucenex Life Sciences Inc.
Dates
Start Oct 2022 · main results expected Oct 2023
NCT05243329 on ClinicalTrials.gov · record updated Jun 2023
Status unknownPhase 2128 participants planned
Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)
Conditions
Alcohol Use Disorder
Canadian sites
Calgary, Alberta; Kelowna, British Columbia; Surrey, British Columbia; Vancouver, British Columbia; Halifax, Nova Scotia; Hamilton, Ontario; Kingston, Ontario; Toronto, Ontario
Lead sponsor
Clairvoyant Therapeutics
Dates
Start May 2022 · main results expected Aug 2024
NCT05646303 on ClinicalTrials.gov · record updated Aug 2024

How to read this list.

Status is the registry’s own: “Recruiting” means the study says it is enrolling now; “Not yet recruiting” has not started; “Under way” covers studies that are running but not enrolling, or enrolling by invitation only.
Phase describes the stage of drug research. The registry’s glossary explains each phase.
Conditions are the terms each study registered. Our condition groups only sort them for the filter; the full terms are on each card.
Studies register themselves and update their own records, so a status can be out of date. The “record updated” date on each card says when its team last changed it.

Keep reading.

We list what the registry lists; we don’t verify or endorse any study. Spotted a Canadian psilocybin study that’s missing? It needs a ClinicalTrials.gov record to appear here.